Stimulating Solutions

Soterix provides clinicians and patients with the most safe, effective, and user friendly neuromodulation technology.

Read More

Advanced Technology

The most advanced biomedical research and technology at the push of a button. Soterix tDCS devices feature patented stimulation technologies and unparalleled precision.

Device Features

One Patient At A Time

Individually designed therapies with the power to transform lives. Soterix Solutions enables individualized therapy design for a highly versatile and adaptable tDCS treatment.

Custom Solutions

Clinical Trials Stimulator

The Soterix Clinical Trials stimulator is the most advanced and customizable system for true double-blind control trials.

CT-tDCS Features

Limited Total Energy

The Soterix 1×1 Limited Total Energy device is especially designed for stimulation on susceptible subjects.

LTE tDCS Features

EASYKit

Introducing the EASYKit – everything you need for a complete tDCS session in a box.

See what's included

Accessories

Individual accessories and pre-packaged kits for tDCS clinical trials, including the EASYpad™ sponge electrodes with conductive rubber insets, elastic fastener, EASYStrap and more.

Browse tDCS Accessories

HD-tDCS in Nature News

Our exclusive "X configuration" overcomes limitations of conventional tDCS. Soterix HD-tDCS can "penetrate deeper into the brain in more focused areas", reports Nature News.

Industry Standard

Physicians at Harvard Medical School demonstrate the application of tDCS for clinical trial on patients using a Soterix 1x1 device in this Journal of Visualized Experiments video.

tDCS EASY-Kit

Soterix EASY-Kits include everything you need for a complete tDCS session in a compact container. Compatible with all Soterix 1x1 Stimulators and Accessories and includes Soterix EASY-Pads.

tDCS for Clinical Trials

The CT-tDCS platform is the most sophisticated system for clinical trials with tDCS and the only system to provide true double-blind control and online subject monitoring.

Fibromyalgia Clinical Trial

HD-tDCS clinical trial underway for fibromyalgia at Harvard Medical School and Spaulding Rehabilitation Hospital, Boston.

Stroke Rehab. Clinical Trial

NIH grants Soterix a Phase-1 STTR grant to develop HD-tDCS for stroke rehabilitation. The first technology capable of delivering therapeutic direct current to target brain regions involved in functional recovery.

Depression Clinical Trial

For the most comprehensive tDCS trial to-date, researchers selected the most advanced tDCS device and the only system optimized for clinical trials – The Soterix Medical 1x1-CT.

Pediatric Epilepsy Trial

Epilepsy Foundation awards a New Therapy Grant for a clinical trial of High-Definition tDCS in pediatric epilepsy. Dr. Alexander Rotenberg will lead a team of clinical investigators including at BCH and Harvard Medical School.

Stroke Rehab. Trial

NIH grants Burke Medical Research Institute $3m to conduct the most controlled trial of tDCS for stroke rehabilitation to date. The Soterix Medical 1x1 platform is the most advanced and the industry standard for tDCS clinical trials for rehabilitation.

Down Syndrome Trial

Soterix Medical Inc. receives FDA Clinical Trial IDE for High-Definition tDCS (HD-tDCS) to improve IQ in pediatric Down syndrome. HD-tDCS is the only non-invasive, brain targeted, and low-intensity technology designed to promote neuroplasticity.

Pediatric Hemiparesis Trial

Dr. Bernadette Gillick's Pediatric Rehabilitation Laboratory is supported by the NIH and University of Minnesota Clinical and Translational Science Institute to investigate the use of a form of tDCS for interventions in rehabilitation for children. Subject specific analysis with Soterix Medical Neurotargeting™ will guide current to brain cells in the injured part of the brain.